TFA Therapeutics annual ebitda
2021
2022
2023
2024
2025
TFA Therapeutics EBITDA Growth & History (RAJAF)
TFA Therapeutics's calculated EBITDA was −$5,885 for fiscal 2025.
View full TFA Therapeutics company overviewTFA Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$5,885 | −$229,237 | — |
| 2024 | 2024-12-31 | $223,352 | −$61,238 | −21.52% |
| 2023 | 2023-12-31 | $284,590 | $675,221 | — |
| 2022 | 2022-12-31 | −$390,631 | −$420,482 | — |
| 2021 | 2021-12-31 | $29,851 | — | — |
TFA Therapeutics ebitda trends
Between the periods ended 2021-12-31 and 2025-12-31, TFA Therapeutics's ebitda decreased from $29,851 to −$5,885, a change of −$35,736.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TFA Therapeutics source filings ↗